InvestorsHub Logo
Followers 0
Posts 72
Boards Moderated 0
Alias Born 01/04/2017

Re: learningcurve2020 post# 7499

Monday, 11/19/2018 2:13:41 PM

Monday, November 19, 2018 2:13:41 PM

Post# of 9818
Broken record???? Are you serious Clark(referencing xmas vacation, LC is not named Clark, or is it)? Have you looked in the mirror lately champ? Last time I threw up do diligence which was significant, you said it wasn't and called me a snowflake, and that hurt... I don't know if I will ever get over it

How about this her is some more DD:
The Company has developed a strategy to increase the efficacy and lessen the toxicity of cancer chemotherapy by binding heavy metals and coupling chemotherapeutic drugs to the serum protein transferrin. Transferrin is the serum protein that transports iron to sites of absorption, utilization and storage. Iron is an essential micronutrient for DNA synthesis, and all cancer cells require very large amounts of iron for DNA synthesis and rapid cell growth. Cancer cells express 100 to 1,000-fold greater numbers of transferrin receptors on their cell surface than normal cells.

Therefore, with our transferrin transport technology (TTT), we can deliver cytotoxic agents targeted selectively to the cancer cell, and thus, have little effect on normal cells.

Our transferrin compounds are of three types:
•Heavy metals bound to the physiologic binding sites of the transferrin molecule
•Drugs conjugated to the molecule by a gluteraldehyde coupling process.
• Drugs trapped in protein molecules.

These agents alone and in combination with other cancer therapies, demonstrate tremendous cancer cell killing with little effect on normal cells. They have been shown to potentiate the effect and lessen the toxicity of conventional chemotherapy if given as pretreatment prior to the chemotherapy. One of the compounds (cis-platinum-transferrin) has been shown to be an especially good radiation sensitizer, and potentiate the effects of doxorubucin when used as a pretreatment agent.



Transferrin is the CD71 receptor on cells with various malignancies in solid tumors, which could be huge after the company initiates the trials and gets back in the lab with the push in individualized therapy.

How about we have a question on this on the CC?

Once again LC, please back your claims with DD.

HDOGG
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent THER News